Rapamycin treatment has been also tested in animal models of AD where it reduced the accumulation of Aβ aggregates and prevented tau phosphorylation in the brain of AD transgenic mice, showing a global impact in cognition maintenance (Spilman et al., 2010). Here, MAPT is linked to Alzheimer disease.